Search

A substantial proportion of cardiovascular morbidity and mortality in developing countries is caused by cardiac complications of 'neglected diseases', such as Chagas disease, endomyocardial fibrosis, and rheumatic heart disease. Here, Yacoub et al. discuss management strategies for what they believe are potentially preventable diseases.

'End-stage' hypertrophic cardiomyopathy (HCM) is one of the most serious manifestations of HCM, yet its etiology remains poorly understood. Here, Yacoub et al. discuss recent advances in our knowledge of end-stage HCM, explore avenues for future research, and propose that elucidating this 'mysterious' condition might provide a model for other myocardial diseases.

In this article, Professors Yacoub and Miller review the current status of left-ventricular-assist-device (LVAD) therapy for patients with chronic heart failure. The authors discuss the advantages and disadvantages of the available devices, how the indications for LVADs have evolved, and address the question 'are LVADs ready for long-term use?'

The prevalence of valve disease is increasing worldwide. Given the need to reduce the occurrence of complications experienced with mechanical and tissue valve replacements, and the realization that normal heart valves perform extremely complex functions, tissue engineering of heart valves appears to be the next logical step. In this Viewpoint, Magdi Yacoub and Johanna JM Takkenberg discuss the future of tissue engineered heart valves.

Hypertrophic cardiomyopathy is a widespread condition that is often neglected and undiagnosed. Although there are still large gaps in our knowledge of the basic disease mechanisms, population studies have shown us that patients can have normal life expectancy but often develop disease-related complications. In this Viewpoint, Franco Cecchi, Magdi Yacoub and Iacopo Olivotto highlight the disease's screening and treatment, and some of the exciting new knowledge in the field.

November 2019 marks 15 years since the launch of Nature Reviews Cardiology. To celebrate, we invited six of our Advisory Board members to discuss some of the highlights of cardiovascular research in the past 15 years and to make some projections about scientific research in the next 15 years.

Cardiac transplantation research has focused on predicting risk and determining pathogenic pathways, and hence finding targets for intervention. As the Human Genome Project is now ready to provide the information required for personalized treatment, this Viewpoint discusses genetic association studies and their potential application at different stages before and after cardiac transplantation.

The authors highlight the benefits of using a beating-heart technique during surgical correction of myocardial bridging in this 10-year-old patient with nonobstructive hypertrophic.cardiomyopathy.